Matches in SemOpenAlex for { <https://semopenalex.org/work/W14543932> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W14543932 endingPage "985" @default.
- W14543932 startingPage "962" @default.
- W14543932 abstract "Around one million people in Japan are suffering from adenoviral conjunctivitis every year and it is recognized as one of the major pathogens of nosocomial infection. Several complications, such as corneal erosion and conjunctival pseudomembrane, are observed in some of the cases and corneal sube- pithelial opacity may bring visual impairment. Moreover, no specific anti-adenoviral agent has been discovered and an effective treatment has not been established for adenoviral infection. We have researched new medical treatment for viral conjunctivitis based on recent findings in adenoviral conjunctivitis. Firstly, anti-adenoviral activity was evaluated in vitro in agents which could possibly act as anti-adenoviral drugs. Twelve candidates, such as zalcitabin, interferon beta, etc., were selected among antiviral drugs, adenoviral receptor inhibitors, natural products and anti-inflammatory drugs. Remarkable anti-adenoviral effect was observed in zalcitabin, sanilbudine, interferon beta and anti-osteopontin peptide. Two anti-human immunodeficiency virus (HIV) drugs with anti-adenoviral activity, zalcitabin and sanilbudine, are nucleoside reverse transcriptase inhibitors, but, in contrast, non-nucleoside reverse transcriptase inhibitors and protease inhibitors were ineffective against adenovirus. Interferon beta and anti-osteopontin peptide displayed anti-adenoviral effects by absorption inhibition. Secondly, side effects caused by possible anti-adenoviral eye drops, including cidofovir whose development as eye drops against eyeball and ocular adnexa had been suspended, were analyzed in a white rabbit model. In animals given cidofovir locally, significant narrowing of lacrimal canaliculus, redness of eyelid and conjunctival injection was observed, but obstruction of the lacrimal duct was not found. Although zalcitabin and sanilbudine eye drops induced eyelid redness, no change was observed in the lacrimal route and conjunctiva. In animals treated by cidofovir, inflammation histologically suggesting mainly allergic change was observed. These results indicate that these four drugs are possible candidate for safe eye drops against adenoviral conjunctivitis. These four agents are divided into two categories, inhibitors of adenoviral replication, zalcitabin and sanilbudine; and suppressors of adenoviral infection, interferon beta and anti-osteopontin peptide. It is expected that eye drops for specific treatment of adenoviral conjunctivitis are going to be available in the near future following investigation of therapeutic effect in adenoviral infected animals and clinical trials in humans." @default.
- W14543932 created "2016-06-24" @default.
- W14543932 creator A5011514460 @default.
- W14543932 date "2005-12-01" @default.
- W14543932 modified "2023-09-23" @default.
- W14543932 title "New medical treatment for viral conjunctivitis" @default.
- W14543932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16408491" @default.
- W14543932 hasPublicationYear "2005" @default.
- W14543932 type Work @default.
- W14543932 sameAs 14543932 @default.
- W14543932 citedByCount "0" @default.
- W14543932 crossrefType "journal-article" @default.
- W14543932 hasAuthorship W14543932A5011514460 @default.
- W14543932 hasConcept C104317684 @default.
- W14543932 hasConcept C118487528 @default.
- W14543932 hasConcept C156719811 @default.
- W14543932 hasConcept C159047783 @default.
- W14543932 hasConcept C2522874641 @default.
- W14543932 hasConcept C2776824251 @default.
- W14543932 hasConcept C2778560704 @default.
- W14543932 hasConcept C49105822 @default.
- W14543932 hasConcept C55493867 @default.
- W14543932 hasConcept C71924100 @default.
- W14543932 hasConcept C86803240 @default.
- W14543932 hasConcept C98274493 @default.
- W14543932 hasConceptScore W14543932C104317684 @default.
- W14543932 hasConceptScore W14543932C118487528 @default.
- W14543932 hasConceptScore W14543932C156719811 @default.
- W14543932 hasConceptScore W14543932C159047783 @default.
- W14543932 hasConceptScore W14543932C2522874641 @default.
- W14543932 hasConceptScore W14543932C2776824251 @default.
- W14543932 hasConceptScore W14543932C2778560704 @default.
- W14543932 hasConceptScore W14543932C49105822 @default.
- W14543932 hasConceptScore W14543932C55493867 @default.
- W14543932 hasConceptScore W14543932C71924100 @default.
- W14543932 hasConceptScore W14543932C86803240 @default.
- W14543932 hasConceptScore W14543932C98274493 @default.
- W14543932 hasIssue "12" @default.
- W14543932 hasLocation W145439321 @default.
- W14543932 hasLocation W145439322 @default.
- W14543932 hasOpenAccess W14543932 @default.
- W14543932 hasPrimaryLocation W145439321 @default.
- W14543932 hasRelatedWork W1985918359 @default.
- W14543932 hasRelatedWork W2001843565 @default.
- W14543932 hasRelatedWork W2019177524 @default.
- W14543932 hasRelatedWork W2059917587 @default.
- W14543932 hasRelatedWork W2092976200 @default.
- W14543932 hasRelatedWork W2148199779 @default.
- W14543932 hasRelatedWork W2399961639 @default.
- W14543932 hasRelatedWork W2403405479 @default.
- W14543932 hasRelatedWork W2416846842 @default.
- W14543932 hasRelatedWork W2417743434 @default.
- W14543932 hasRelatedWork W2626750568 @default.
- W14543932 hasRelatedWork W2735712293 @default.
- W14543932 hasRelatedWork W2883728346 @default.
- W14543932 hasRelatedWork W3022802917 @default.
- W14543932 hasRelatedWork W3057593170 @default.
- W14543932 hasRelatedWork W3129799950 @default.
- W14543932 hasRelatedWork W5529407 @default.
- W14543932 hasRelatedWork W883653421 @default.
- W14543932 hasRelatedWork W2187080241 @default.
- W14543932 hasRelatedWork W2872890642 @default.
- W14543932 hasVolume "109" @default.
- W14543932 isParatext "false" @default.
- W14543932 isRetracted "false" @default.
- W14543932 magId "14543932" @default.
- W14543932 workType "article" @default.